Cell coding specialist Bit Bio has signed an agreement with AIM-listed reagent distributor Abcam to make its iPSC derived functional human cells available to the global life science community.
The first product available is brain cells serving the neuroscience community.
Bit Bio is addressing access to human cells, a significant bottleneck in medical research and drug development, through a precise reprogramming proprietary technology platform that enables uniquely efficient and consistent production of human cells.
“Bit Bio’s goal is to develop a scalable technology platform capable of producing consistent batches of every human cell type,” said Bit Bio chief executive Mark Kotter, a neurosurgeon at Cambridge University, and stem cell biologist.
“This agreement will accelerate our mission of putting highly defined human cells in the hands of the researchers who need them to pursue their life-saving work.”
“Supporting enhanced access to complementary technologies that have the potential to improve and accelerate research is part of our growth strategy,” said John Baker, Senior Vice President Product Portfolio and Innovation at Abcam.